Industry / Russia

Biotech Sector Could Learn From The US

March 2008 | Industry News

Printable version
Bookmark

Russia should adopt more market reforms in order to replicate some of the successes achieved by the US's biotechnology sector, according to a recent report by the Washington Legal Foundation.

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Protek Seeks To Grow Production & Retail Businesses Through US$400mn IPO

Industry / Russia Vertically-integrated Russian pharmaceutical enterprise Protek plans to raise US$400mn through an initial public offering (IPO) in May or June 2010. Half the amount raised will be used to purchase additional...

April 2010

AstraZeneca Targets 28% Growth For 2010

Industry / Russia Anglo-Swedish pharmaceutical company AstraZeneca intends to build upon positive revenue performance in Russia during 2009. The drugmaker will attempt to drive sales growth rates by expanding its innovative...

March 2010

Price Monitoring Reveals Strong Inflation And Breaches Of Limits

Industry / Russia Pharmaceutical prices in Russia and Ukraine have been under intense scrutiny since the latter part of 2008, as a result of negative economic conditions, associated currency devaluations and profiteering...

March 2010

Small Steps Towards GMP Compliance

Industry / Russia Aligning Russian pharmaceutical manufacturing with international standards is an essential measure if the country is to build a domestic industry capable of competing with more developed multinational...

March 2010

Pharmaceutical Production Down In 2009

Industry / Russia Russia's pharmaceutical manufacturing industry was hit hard during 2009, with production amounting to only 91.7% of 2008 levels, according to data released by the Ministry of Industry and Trade of the...

February 2010